Table 2

Summary of extent of involvement in patients with HZ

Categories, n (%)*MTX monotherapy
(n=314)
ADA 40 mg EOW + MTX (n=579)Any UPA
15 mg QD
(n=3209)
Any UPA
30 mg QD
(n=1204)
Total patients with ≥1 HZ event5 (1.6)11 (1.9)204 (6.4)150 (12.5)
Single dermatome5 (100)9 (81.8)153 (75.0)110 (73.3)
Ophthalmic involvement02 (18.2)13 (6.4)3 (2.0)
Meningoencephalopathic involvement0001 (0.7)
Unilateral involving multiple dermatomes†0035 (17.2)27 (18.0)
HZ oticus
(Ramsay Hunt syndrome)
002 (1.0)1 (0.7)
Disseminated, cutaneous only (no CNS involvement)‡01 (9.1)12 (5.9)11 (7.3)
Disseminated with other non-cutaneous organ involvement (no CNS involvement)§0000
Postherpetic neuralgia¶01 (8.3)17 (7.2)13 (7.2)
Hospitalisations because of HZ event¶0011 (4.7)15 (8.3)
Missing005 (2.5)2 (1.3)
  • *Patients may fall into >1 category.

  • †≤2 adjacent dermatomes.

  • ‡≥3 dermatomes, unilateral non-adjacent dermatomes or bilateral dermatomes.

  • §Involvement of visceral organs (eg, HZ pneumonia or HZ hepatitis).

  • ¶Percentages based on total number of HZ events.

  • ADA, adalimumab; CNS, central nervous system; EOW, every other week; HZ, herpes zoster; MTX, methotrexate; QD, once daily; UPA, upadacitinib.